Background <p>For patients with high-risk melanoma who are unresponsive or intolerant to immune checkpoint inhibitors, cancer vaccines may provide benefit with a favorable toxicity profile. CD4<sup>+</sup> T cells provide essential help to dendritic cells (DCs) for optimal CD8<sup>+</sup> T cell priming in the antitumor response, and induction of tumor-cognate CD4<sup>+</sup> T cell responses may enhance vaccine efficacy. We report on…
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)
Journal for ImmunoTherapy of Cancer | | Ninmer, E. K., Petroni, G. R., Gastman, B. R., Gaughan, E. M., Isaacs, J. M., Haden, K., Kaur, V., Wages, N. A., Chianese-Bullock, K. A., Smith, K. T., Wright, P., Bryant, J., Dunlap-Brown, M., Engel, J. A., Bekiranov, S., Mauldin, I. S., Truong, T.-G., Bullock, T. N. J., Slingluff, C. L.
Topics: skin-cancer, cervical-cancer, immunotherapy, clinical-trials
Read the full article at Journal for ImmunoTherapy of Cancer